Genzyme: The Renvela Launch Decision Harvard Case Solution & Analysis

Pharmaceutical company Genzyme has created a brand new drug, Renvela, which is a phosphate binder designed to be used primarily by patients with kidney failure. Renvela is a slightly different variant of Genzyme's highly successful Renagel.

Company executives must now determine how best to start Renvela. Should it be a premium version of Renagel? Is it worth establishing the product whatsoever? The instance seems fairly straightforward on the surface, but the questions are challenging to work through.

PUBLICATION DATE: July 01, 2009 PRODUCT #: KEL412-PDF-ENG

This is just an excerpt. This case is about SALES & MARKETING

Share This

SALE SALE

Save Up To

30%

IN ONLINE CASE STUDY

FOR FREE CASES AND PROJECTS INCLUDING EXCITING DEALS PLEASE REGISTER YOURSELF !!

Register now and save up to 30%.